GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (STU:7XB) » Definitions » Additional Paid-In Capital

Xbrane Biopharma AB (STU:7XB) Additional Paid-In Capital : €124.81 Mil(As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Xbrane Biopharma AB Additional Paid-In Capital?


Xbrane Biopharma AB's quarterly additional paid-in capital increased from Sep. 2023 (€120.75 Mil) to Dec. 2023 (€127.71 Mil) but then stayed the same from Dec. 2023 (€127.71 Mil) to Mar. 2024 (€124.81 Mil).

Xbrane Biopharma AB's annual additional paid-in capital increased from Dec. 2021 (€110.44 Mil) to Dec. 2022 (€117.73 Mil) and increased from Dec. 2022 (€117.73 Mil) to Dec. 2023 (€127.71 Mil).

Xbrane Biopharma AB Additional Paid-In Capital Historical Data

The historical data trend for Xbrane Biopharma AB's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xbrane Biopharma AB Additional Paid-In Capital Chart

Xbrane Biopharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.76 76.05 110.44 117.73 127.71

Xbrane Biopharma AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 115.38 121.20 120.75 127.71 124.81

Xbrane Biopharma AB Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Xbrane Biopharma AB Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Xbrane Biopharma AB's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Xbrane Biopharma AB (STU:7XB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (STU:7XB) » Definitions » Additional Paid-In Capital
Comparable Companies
OSTO:DMYD B OSTO:CANTA XSAT:CURAS OSTO:ONCO OSTO:SYNACT OSTO:ITECH OSTO:INIT OSTO:IVACC OSTO:INDEX OSTO:KDEV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
XBRANE:Sweden 7XB:Germany
Address
Retzius vag 8, Solna, SWE, 171 65
Website
https://www.xbrane.com
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company has a patented protein production platform with up to 12 times greater productivity than standard systems for the production of proteins in E.coli host cells. Xbrane's leading product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. The company's geographical segments include the Middle East, Asia, Europe, and the United States.

Xbrane Biopharma AB (STU:7XB) Headlines

No Headlines